Where the peptide enters the body determines where it concentrates, how much reaches systemic circulation, and which tissues it can reach at therapeutic levels
This is for educational math only, especially for patients reviewing pharmacy labels
The first GLP-1 drug, exenatide, hit the market in 2005, and since then, companies have engineered more effective versions
Sever'yanova L, Dolgintsev ME
Administered via the nasal passage, this combination potentially accelerates angiogenesis (the formation of new blood vessels), encourages the upregulation of actin and cellular motility, and boosts the expression of essential repair markers like VEGFR2 and EGR-1